Physician profile

Merlin E Brown

Internal Medicine · Edina, MN

NPI 1053317354

$16,091.10

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$92.81
Education$0.79

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Allergan, INC. $13,820.92 2019-2022
Merz North America, INC. $2,125.12 2019-2020
Abbvie INC. $57.07 2023
Daiichi Sankyo INC. $36.91 2019-2020
Ultragenyx Pharmaceutical INC. $35.56 2022-2023
Amgen INC. $14.73 2023 Repatha, Otezla
Sumitomo Pharma America, INC. $0.79 2023 Gemtesa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Merlin E Brown

$16,091.10

in general payments reported 2019-2025

Years
2019-2023
Top company
Allergan, INC.

https://glasscript.com/doctor/820063/merlin-e-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.